Compare · Ingredients

Cysteamine vs Tranexamic Acid

Cysteamine: Can reduce melasma pigmentation in tested topical formulas. Tranexamic Acid: Topical formulas are studied for melasma, with mixed results.

Research updated 2026-10-25

Four cysteamine products: a Senté tube, an Omic+ cream and box, a 5% cysteamine serum dropper and a Cyspera bottle

Five serums lined up on white, labeled tranexamic acid or niacinamide with TXA, including SkinCeuticals Discoloration Defense

Which one?At a glance What it helps Diagrams Using both Strengths Results Safety How it works Questions

Which one is right for you?

Choose Cysteamine if…

Consider for diagnosed melasma when a suitable topical option is needed.

Diagnosed melasma
Hydroquinone isn’t suitable
You can follow short-contact wash-off

Choose Tranexamic Acid if…

Consider a topical pigment option; the evidence is mixed and formula-specific.

Melasma or stubborn dark marks
Skin that dislikes hydroquinone
Daily sunscreen

Often combined

Can you use both?

A useful pairing for melasma; tranexamic acid is gentle alongside cysteamine.

At a glance

● Cysteamine

● Tranexamic Acid

Type

Pigment-targeting active

Pigment-targeting ingredient

What it does

Can reduce melasma pigmentation in tested topical formulas.

Topical formulas are studied for melasma, with mixed results.

Best for

Melasma

Melasma

Studied concentrations

5% cream in controlled melasma trials; contact instructions vary by product.

Topical 5% in the cited trials; oral treatment is a separate medical decision.

When to use

On the schedule specified for the product or prescribed treatment.

On the schedule specified for the product or prescribed treatment.

Time to results

Usually assessed over 8–16 weeks

Usually assessed over 8–16 weeks

Irritation

Odour, stinging and irritation may limit use; follow wash-off instructions.

Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.

Sensitive skin

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Available

Prescription or cosmetic status depends on the active, formula and country; check the label.

Prescription or cosmetic status depends on the active, formula and country; check the label.

What it helps

Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.

Evidence level

Cysteamine

Tranexamic Acid

Moderate evidenceSome supportive research

Flat tan patches with soft irregular edges across the forehead and upper cheek of an adult with light skin, the surface completely smooth.

Melasma

A placebo-controlled trial found reduced pigmentation with 5% cream.

—

Limited evidenceEarly or small studies

—

Flat tan patches with soft irregular edges across the forehead and upper cheek of an adult with light skin, the surface completely smooth.

Melasma

Trials report mixed results, including one with no clear benefit over vehicle.

Insufficient evidence

Flat light-brown residual marks on a fair cheek.

Post-Inflammatory Hyperpigmentation

The cited melasma trial does not establish fading of every type of dark mark.

The front of a forearm on fair skin. Two pale patches with sharp edges sit against lightly tanned skin, and the difference between the patch and the skin around it is subtle.

Vitiligo

The reviewed sources do not establish this ingredient as a treatment for this concern.

Sensitive Skin on light skin.

Sensitive Skin

The reviewed sources do not establish this ingredient as a treatment for this concern.

Flat light-brown residual marks on a fair cheek.

Post-Inflammatory Hyperpigmentation

The cited melasma trials do not establish benefit for all post-inflammatory pigment.

The front of a forearm on fair skin. Two pale patches with sharp edges sit against lightly tanned skin, and the difference between the patch and the skin around it is subtle.

Vitiligo

The reviewed sources do not establish this ingredient as a treatment for this concern.

Post-Inflammatory Redness.

Post-Inflammatory Redness

The reviewed sources do not establish this ingredient as a treatment for this concern.

A relaxed forehead with faint shallow horizontal fine lines.

Wrinkles and Fine Lines

The reviewed sources do not establish this ingredient as a treatment for this concern.

How it works

Cysteamine mechanism diagram. Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter. — Open full-size diagram
Diagram explanation and sources
Affects melanin formation: Cysteamine acts through several pigment pathways. May help melasma: The formula, contact time and tolerance matter.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Source 1

Tranexamic Acid mechanism diagram. Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results. — Open full-size diagram
Diagram explanation and sources
Affects plasmin-related signaling: May reduce signals that stimulate pigment production. May help uneven pigmentation: Delivery and the formula influence topical results.
Schematic illustration; not a measurement of skin penetration. Effects vary with ingredient identity and formulation.
Source 1 · Source 2

Using both in one routine

Built from where each one usually sits in a routine. Introduce one at a time.

Morning

Step 1

Cleanser

Step 2

Tranexamic AcidMorning or night

Step 3

Moisturizer

Step 4

Sunscreen

Night

Step 1

Cleanser

Step 2

Tranexamic AcidMorning or night

Step 3

CysteamineNight

Step 4

Moisturizer

Strengths and forms

Concentrations

5% cysteamine cream is the main concentration studied for melasma. Contact time is product-specific; some studied formulas are short-contact treatments rather than overnight creams.

5%

Studied melasma cream

Controlled trials studied this strength. One short-contact trial used a specific cream; follow the current product’s instructions rather than copying a study schedule.

Choosing a strength: Choose a finished topical product with clear instructions for how long to leave it on and when to rinse.

Higher strengths: There is no established benefit from escalating beyond the studied strength. Burning, redness or a persistent rash are reasons to stop and reassess.

Formula matters: Stabilization, the base cream and exposure time affect tolerability. Different cysteamine formulations need not have identical instructions.

Topical tranexamic acid studies have used different delivery systems, including 1.8% liposomal lotion and 5% creams or solutions. Oral treatment and procedure-assisted delivery are separate medical decisions.

1.8%

5%

Studied liposomal lotion

One melasma trial tested this delivery system. Its percentage cannot be directly compared with an ordinary serum.

Studied topical formulas

Several melasma studies used topical formulas at this strength. Evidence does not establish one best concentration for all pigment concerns.

Choosing a strength: Look for evidence on the finished topical product. Do not use injectable or oral products as DIY skincare.

Higher strengths: A stronger topical percentage has not been shown to guarantee better results. Oral use requires separate evaluation of risks, including clotting risk.

Formula matters: Liposomal delivery, other brightening ingredients and procedures can change the treatment. A microneedling study is not evidence for the same result from a home serum.

Forms

Cream

Serum · Tablet · Injection

When you’ll see results

Approximate windows, not promises.

● Cysteamine

● Tranexamic Acid

First few weeks

First few weeksAssess tolerance first; pigment change is usually slower.

First few weeksAssess tolerance first; pigment change is usually slower.

4–8 weeks

4–8 weeksSome studied regimens begin showing pigment improvement.

4–8 weeksSome studied regimens begin showing pigment improvement.

8–12 weeks

8–12 weeksA useful review point for benefit and irritation.

8–12 weeksA useful review point for benefit and irritation.

3–6 months

3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.

3–6 monthsMany melasma trials assess results over three to four months; recurrence is common.

6–12 months

6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.

6–12 monthsLong-term use depends on the active; follow a monitored plan rather than extending treatment automatically.

Safety and sensitive skin

Common reactions

Odour, stinging and irritation may limit use; follow wash-off instructions.

Can sting or cause redness; do not substitute tablets or injections for a cosmetic product.

When to stop

Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.

Stop for persistent burning, swelling, blistering or a new rash. Seek urgent care for breathing difficulty or a severe allergic reaction.

Sensitive or inflamed skin

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Choose a simple formula and test a small area first. Avoid actively inflamed or broken skin unless the product is specifically directed for it.

Important limits

Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.

Do not use a cosmetic product as a substitute for diagnosis of an unexplained, changing or persistent skin problem.

Pregnancy

Data in pregnancy are limited; ask the clinician managing your pregnancy before using.

Melasma is common in pregnancy, so this comes up constantly. Oral tranexamic acid is not a casual pregnancy decision, and the topical version has little pregnancy-specific data. Ask the doctor managing your pregnancy, since they know your full picture.

How it works

In the skin

On the skin. The finished product delivers cysteamine in a particular vehicle.

Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Conversion. No activation step is established as necessary for its intended topical role.

Skin response. Acts on pigment-related pathways; the cream, contact time and tolerance influence its practical effect.

Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.

On the skin. The finished product delivers tranexamic acid in a particular vehicle.

Entering skin. Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Conversion. No activation step is established as necessary for its intended topical role.

Skin response. May affect plasmin-related signalling involved in pigmentation; a small molecular size does not guarantee delivery.

Additional effects. Proposed pathways do not establish a measured depth of delivery or clinical benefit beyond the studies cited.

Getting in

Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Below the 500 Da guideline; delivery still depends on the formula, solubility, stability and skin condition. Size does not prove effectiveness or penetration depth.

Molecule size

Cysteamine · 77 Da

Tranexamic Acid · 157 Da

Smaller than 500 Da passes the outer skin more easily. Size isn’t an effectiveness score.

500 Da guideline

Common questions

Cysteamine:What should I choose cysteamine for?

Consider for diagnosed melasma when a suitable topical option is needed.

Cysteamine:How strong is the evidence?

A small placebo-controlled study supports 5% cream over four months. Active-comparator studies are small and do not prove equal efficacy to hydroquinone. The mass shown refers to the free base, not its hydrochloride salt.

Tranexamic Acid:What should I choose tranexamic acid for?

Consider a topical pigment option; the evidence is mixed and formula-specific.

Tranexamic Acid:How strong is the evidence?

A small vehicle-controlled 5% trial did not show superiority over vehicle. A larger active-comparator study found improvement in both groups but did not prove equivalence to hydroquinone.

Sources

Sources and further reading

Dermapedia on YouTube